In summary, although deal volume is down, there are fewer but larger deal sizes. Life sciences companies that can demonstrate ...

Meanwhile at SpinCo, a new spinoff of Galapagos, Henry Gosebruch was appointed CEO. Gosebruch was previously president and ...

As has been widely reported on, immunisation rates, including for flu and RSV, have been falling – at a troubling rate – and ...

Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new ...

In particular, the organisation is unhappy with Kennedy's repeated assertions that Alzheimer's research has been dedicated to ...

Final draft guidance from NICE has backed NHS use of Filspari (sparsentan) for primary immunoglobulin A nephropathy (IgAN), ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

Shares in the digital therapeutics (DTx) developer closed up more than 17% after its debut on the NYSE at $32 under the HNGE ...

Pfizer placed a $6.7 billion bet on the outcome of two phase 3 trials of Arena Pharmaceuticals' etrasimod in ulcerative colitis (UC) when it acquired the company earlier this year, and the gamble ...

As NICE begins to incorporate health equity into drug reimbursement decisions, forward-looking pharmaceutical companies have a chance to lead – aligning innovation with access drivers and ...

The UK pharma sector has reacted with consternation to the news that the government is proposing to raise the Statutory Scheme payment rate from 15.5% to 32.2% of companies' NHS sales in the ...

Johnson & Johnson's third attempt to use bankruptcy proceedings to settle lawsuits claiming that its talc-based products harmed consumers has been rejected. In a Houston, Texas court, Judge ...